# Advanced Radiotherapy Cuts Prostate Cancer Treatment Sessions by 75%

Men with prostate cancer in England now have access to a faster treatment option through the National Health Service. Hypofractionated radiotherapy delivers the same dose of radiation in far fewer sessions, reducing treatment from 20 appointments to just five.

This approach concentrates higher doses of radiation into fewer visits. Patients complete their entire course in one to two weeks rather than four to five weeks. The shorter timeline reduces the burden on patients and healthcare systems while maintaining effectiveness.

The NHS adoption follows strong clinical evidence supporting this method. Hypofractionated radiotherapy works by exploiting how cancer cells respond to larger single doses. Prostate cancer cells prove particularly sensitive to this approach, making it suitable for many men with the disease.

Patients benefit beyond convenience. Shorter treatment periods mean fewer trips to hospitals, less time away from work and family, and reduced exposure to radiation across normal tissues surrounding the tumor. Men with early to intermediate-stage prostate cancer represent the primary candidates for this accelerated approach.

Healthcare providers screen patients carefully before recommending hypofractionated radiotherapy. Factors like prostate size, urinary symptoms, and overall health influence whether a man qualifies. Some patients with larger prostates or significant urinary issues may still benefit from traditional longer-course treatment.

This expansion reflects a broader shift in cancer care toward precision medicine and personalized treatment. Rather than applying one protocol universally, clinicians now tailor radiation schedules to match individual tumor biology and patient circumstances.

The NHS decision follows years of clinical trials demonstrating safety and efficacy. Research consistently shows hypofractionated radiotherapy achieves comparable cure rates to conventional approaches while reducing side effects like bowel irritation and urinary dysfunction.

Men newly diagnosed with prostate cancer should discuss all available options with their oncology team. Some may qualify for